Arrowhead Research said this week that it has invested $1 million in its majority-owned subsidiary Calando Pharmaceuticals through the purchase of 60 million shares of preferred stock.
The companies also converted roughly $8 million in Calando debt it owed Arrowhead into equity.
With the transactions, Arrowhead said it now holds about 79 percent of Calando's outstanding equity.